louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06978361: Comparison of Efficacy of Microneedling With Platelet Rich Plasma Vs Microneedling With Topical Insulin in the Treatment of Acne Scars
Official title: Comparison of Efficacy of Microneedling With Autologous Platelet-Rich Plasma vs Microneedling With Topical Insulin in the Treatment of Atrophic Acne Scars
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Post-acne Atrophic Scars
Keywords: Post-acne atrophic scars
Microneedling with autologous Platelet- Rich Plasma
Microneedling with topical insulin
Lead sponsor: Khyber Teaching Hospital
Sponsor class: OTHER
First posted: 2025-05-18
Enrollment: 116
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study compares the outcome of two procedures for the treatment of atrophic acne scars.

Detailed description: Post acne scars develop due to severely inflamed and nodulocystic acne. Numerous methods exist for the treatment of post acne scars including lasers , microneedling and chemical peels etc . This study is to compare the efficacy two procedures.

Eligibility criteria: Inclusion Criteria:

Patients confirmed with post-acne atrophic scars . No prior treatment for scars in last 6 months.

-

Exclusion Criteria:

* Patient with active acne or other skin conditions (e.g eczema , psoriasis). Patients on oral or topical retinoids. Pregnant or lactating Mothers. Patients with recurrent herpes simplex infection. Previous Hx of keloids / hypertrophic scarring. Deranged blood glucose levels. Bleeding disorders

Primary outcomes:
measure: Efficacy of treatment
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Peshawar
country: Pakistan
facility: Khyber Teaching Hospital
state: KPK ,Pakistan
Study officials:
References:
Clinical trial NCT04978883: Interstitial Lung Diseases in Primary Sjogren's Syndrome
Official title: Characteristics of Patients With Primary Sjögren's Syndrome Associated Interstitial Lung Disease and Relevant Features of Disease Progression
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sjogren's Syndrome
Lead sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor class: OTHER
First posted: 2021-07-27
Enrollment: 170
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Eighty-five patients with pSS-ILD were identified, and 85 patients with pSS non-ILD were used for comparison. The average age at disease onset and median disease duration in patients with pSS-ILD were greater when compared with pSS non-ILD patients. There was no difference regarding presenting symptoms at disease onset between pSS-ILD and pSS non-ILD patients.

Brief summary: Patients with pSS seen in the Division of Rheumatology, the second affiliated hospital of Zhejiang University, School of Medicine (SAHZU) during January 2016 to July 2018, were retrospectively reviewed. Characteristics were analyzed.

Detailed description: Patients with pSS were retrospectively reviewed, and pSS-ILD and pSS non-ILD were identified. Clinical data, laboratory parameters, pulmonary high-resolution CT (HRCT), and pulmonary function tests (PFTs) were collected. pSS-ILD patients were further categorized into subgroups according to HRCT patterns or PFTs.

Eligibility criteria: Inclusion Criteria:

* All patients with pSS fulfilled the 2002 revised version of the European criteria proposed by the American-European Consensus Group
* Patient with pSS evaluated with pulmonary HRCT and/or PFTs were included in the pSS-ILD group

Exclusion Criteria:

* patients with hepatitis C infection, past head and neck radiation treatment, sarcoidosis, acquired immunodeficiency syndrome, pre-existing lymphoma, graft-versushost disease, and use of anticholinergic drugs, IgG4-related disease
* Patients with other connective tissue diseases (CTD) or other pulmonary diseases were further excluded, including those with pulmonary arterial hypertension, pulmonary infections, tuberculosis, chronic bronchitis, emphysema, asthma, chronic obstructive pulmonary disease, malignancies, pulmonary lesions related with environmental, occupational or medication exposures, or history of smoking

Primary outcomes:
measure: observational study, data analysis to identify the risk factors of pSS-ILD
timeFrame: 6 months from baseline
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Second Affiliated Hospital, School of Medicine, Zhejiang University
name: Chen
role: STUDY_CHAIR
References:
Clinical trial NCT00242528: Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.
Official title: Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE4
Conditions: Multiple Myeloma
Keywords: Bone Lesions
Multiple Myeloma
zoledronic acid
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2005-10-20
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate the safety and tolerability of intravenous zoledronic acid in the treatment of patients with multiple myeloma stage III with bone lesions related to Cancer.


Eligibility criteria: Inclusion Criteria:

* Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2.
* Confirmed Diagnosis of Durie-Salmon Stage III Multiple Myeloma, with the following clinical characteristics:

A. At least 1 osteolytic bone lesion demonstrable in a conventional X-ray film. B. The patient will have to be receiving treatment for primary neoplasia, at the time of the start of this trial.

- Ambulatory patients aged ≥ 18 years.

Exclusion Criteria:

* Treatment with bisphosphonates in any moment during the last 12 months before visit 1. except for those patients that received only one dosis of bisphosphonates for any indication and when the administration has been 14 days before or older.
* Patients with an absence of a bone lesion clearly related to the primary cancer, and that is detectable in a conventional bone X-ray (simple film).
* Patients with a Serum Calcium level of ≤ 8 g/dl (2.00 mmol/L) or ≥ 12 mg/dL (3.00 mmol/L)
* Treatment with other investigational drugs within 30 days before inclusion in the trial.
* Serum Creatinine levels of \> 3 mg/dl (265 umol/L).
* Total Billirubin levels of \> 2.5 mg/dl (43 umol/L)
* Patients with a heart condition that has the NYHA criteria for a Grade III and IV functional class

Other protocol-defined inclusion/exclusion criteria may apply.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Novartis
name: Novartis
role: STUDY_CHAIR
References:
Clinical trial NCT03662828: Epidemiological Description of the Kaposi's Disease in France's Southeast
Official title: Epidemiological Description of the Kaposi's Disease in France's Southeast
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Kaposi's Disease
Keywords: Kaposi's disease
HHV8
Prevalence
Lead sponsor: Direction Centrale du Service de Santé des Armées
Sponsor class: OTHER
First posted: 2018-09-10
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Diagnosed patients with a Kaposi's disease by biopsy from January 2007 to December 2017

Brief summary: The purpose of this study is to evaluate the prevalence of the Kaposi's disease in France's southeast on 10 years (from 2007 to 2017)

Detailed description: Kaposi's disease is a multifocal disease with cutaneous expression in more than 95% of cases.

There are 4 forms : Mediterranean, Endemic (Sub-Saharan Africa), iatrogenic and epidemic (HIV) The physiological hypotheses to explain the disease are not clear. A proliferation of immunity cells in blood vessels and also an undetermined role of the human herpes virus 8 (HHV-8) could be involved.

The treatment is complex and not standardized. There are a lot of different treatments.

The purpose of this study is to evaluate the prevalence and described the characteristics and the treatment of the Kaposi's disease in the France's southeast on 10 years, from 2007 to 2017.

Eligibility criteria: Inclusion Criteria:

* Diagnosed patients with a Kaposi's disease by biopsy from January 2007 to December 2017

Exclusion Criteria:

* Opposition to the use of personal data

Primary outcomes:
measure: Prevalence of Kaposi's disease
timeFrame: 10 years (2007-2017)
Secondary outcomes:
measure: Descriptive analysis of the different form of the Kaposi's disease in the population
timeFrame: 10 years (2007-2017)
measure: Descriptive analysis of the population : sociodemographic
timeFrame: 10 years (2007-2017)
measure: Descriptive analysis of the population : paraclinical
timeFrame: 10 years (2007-2017)
measure: Descriptive analysis of the population : clinical
timeFrame: 10 years (2007-2017)
measure: Descriptive analysis of the population : therapeutic
timeFrame: 10 years (2007-2017)
measure: Survival analysis
timeFrame: 10 years (2007-2017)
Other outcomes:
Locations:
city: Nice
country: France
facility: Centre Antoine Lacassagne
state: Alpes-Maritimes
city: Nice
country: France
facility: CHU Nice
state: Alpes-Maritimes
city: Marseille
country: France
facility: HIA Laveran
state: Bouche Du Rhone
city: Fréjus
country: France
facility: CHI de Fréjus
state: Var
city: Toulon
country: France
facility: Hôpital d'Instruction des Armées Sainte-Anne
state: Var
Study officials:
References:
Clinical trial NCT04164628: Evaluation of Quality of Life in Women
Official title: Investigation of Affecting Factors Quality of Life in Women
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Quality of Life
Women Health
Social Interaction
Keywords: quality of life
depression
anxiety
social function
Lead sponsor: Hacettepe University
Sponsor class: OTHER
First posted: 2019-11-15
Enrollment: 227
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: 300 women will be evaluated in this study. Their quality of life, level of physical activity, Social Functioning, levels of depression and musculoskeletal status will be assessed.

Detailed description: Many factors affects quality of life in women. In the literature, factors affecting the quality of life such as diseases, working conditions and psychological factors of women have been investigated in different diseases. However, there was no study investigating the factors affecting quality of life for a sample of adult female individuals. Therefore, the aim of our study is to investigate the effect of social, psychological and physical variables that we think may affect the quality of life in women.

Eligibility criteria: Inclusion Criteria:

* To be a volunteer

Exclusion Criteria:

* having severe musculoskeletal system disorders

Primary outcomes:
measure: Quality of life
timeFrame: 5 minutes
Secondary outcomes:
measure: Social Functioning Scale
timeFrame: 10 minutes
measure: Depression scale
timeFrame: 5 minutes
measure: physical activity level
timeFrame: 5 minutes
measure: Musculoskeletal status
timeFrame: 5 minutes
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Hacettepe University
Study officials:
References:
Clinical trial NCT06733428: Agreement and Precision Study
Official title: TRK-3 Agreement and Precision of Pachymetry Function
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Eye Abnormalities
Normal Eyes
Lead sponsor: Topcon Corporation
Sponsor class: INDUSTRY
First posted: 2024-12-13
Enrollment: 108
Sex: ALL
Minimum age (years): 22
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects seeing an eye doctor that have normal cornea, cornea abnormality, or glaucoma

Brief summary: To evaluate the performance of pachymetry function


Eligibility criteria: Inclusion Criteria:

* Provide voluntary written consent
* Age at least 22 years old
* For glaucoma group only, visual field defect and optic nerve damage consistent with glaucoma
* For cornea group only, cornea abnormality

Exclusion Criteria:

* Ocular condition that may affect ability to perform cornea measurements
* Have or is suspected to have ocular infection
* Unable to tolerate eye testing

Primary outcomes:
measure: Cornea thickness
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Chicago
country: United States
facility: Illinois College of Optometry
state: Illinois
Study officials:
References:
Clinical trial NCT06420128: Interprofessional Collaborative Practice in Primary Care: Potentially Avoidable Hospitalization
Official title: Collaborative Practice in Primary Care: a Comparison of the Global Rate of Potentially Avoidable Hospitalization, Depending on Whether Their General Practitioner is Part of a Primary Care Team. A Cohort Study With a 36-month Follow-up.
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Hospitalization
Aged
Primary Health Care
Keywords: Collaborative practice
Seniors
Potentially avoidable hospitalization
Primary Care Team
Lead sponsor: Nantes University Hospital
Sponsor class: OTHER
First posted: 2024-05-17
Enrollment: 500000
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Seniors

Brief summary: The World Health Organization supports collaborative practice in primary care, defining it as "when multiple health professionals from different professional backgrounds work together with patients, families, carers and communities to deliver the highest quality of care across settings" (1). Previous research have shown that collaborative practice in primary care improves care pathways, efficiency of care (2,3), job satisfaction among health professionals (4-6), and economic efficiency (3,7). Riverin et al. found a reduction in post-hospitalization mortality with collaborative practice (8).

In France, the establishment of primary care teams following the American model of Centered Medical Homes is encouraged. In the Pays de la Loire region, two models exist: A national and a regional model.

A major issue for patient care team is the care of seniors (9,10).Hospitalizations can have adverse health effects for this population (11,12). 45% of emergency admissions follow by a hospitalization concern them (13).

The hypothesis of the study is that collaborative practice could reduce the global rate of potential avoidable hospitalizations among seniors.


Eligibility criteria: Inclusion Criteria:

* Patients over 75 years old and over 65 years old with chronic disease(s), with a general practitioner in Pays de la Loire, affiliated with the general health insurance system and have had at least one healthcare encounter, and residing in the Pays de la Loire region.

Exclusion Criteria:

* Patients whose general practitioner has ceased their practice or changed their affiliation, as well as patients who have switched to a new general practitioner.

Primary outcomes:
measure: Comparison of Global rate of potentially avoidable hospitalization
timeFrame: 36 months
Secondary outcomes:
measure: Comparison of criterion of quality
timeFrame: 36 months
measure: Comparison of Global rate of potentially avoidable hospitalization depending the model of primary care team
timeFrame: 36 months
measure: Medico-economic evaluation
timeFrame: 36 months
Other outcomes:
Locations:
city: Nantes
country: France
facility: University Hospital
Study officials:
References:
Clinical trial NCT02773628: Impact of Reduction of Dust Mite Allergenic Load on Step Down of Inhaled Corticosteroids in Stable Asthma
Official title: Impact of Reduction of Dust Mite Allergenic Load on Step Down of Inhaled Corticosteroids in Stable Asthma
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Asthma
Lead sponsor: Centre Hospitalier Universitaire Saint Pierre
Sponsor class: OTHER
First posted: 2016-05-16
Enrollment: 3
Sex: ALL
Minimum age (years): 16
Maximum age (years): 100
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Eviction methods for dust mite allergy have been evaluated in asthma control in a recent Cochrane meta-analysis. None have shown efficacy on asthma control and there are not recommended. The purpose is to evaluate the efficacy of a new commercialized system (Acar'Up) to decrease dust mite load and to assess its impact on the possibility to perform inhaled corticosteroids step down in stable asthmatics.

Detailed description: Eviction methods for dust mite allergy have been evaluated in asthma control in a recent Cochrane meta-analysis. None have shown efficacy on asthma control and there are not recommended. The purpose is to evaluate the efficacy of a new commercialized system, Acar'Up (a spray pulverized on a technical textile that traps the dust mite) to decrease dust mite load and to assess its impact on the possibility to perform inhaled corticosteroids step down in stable asthmatics.

Eligibility criteria: Inclusion Criteria:

* confirmed asthma diagnosis
* controlled asthma for more than 3 months
* treatment with inhaled corticosteroids
* dust mite allergy proved by skin tests ou specific immunoglobulin E

Exclusion Criteria:

* chronic obstructive pulmonary disease, bronchiectasis, Fibrosis, tuberculosis
* asthma-chronic obstructive pulmonary disease overlap syndrome
* ongoing desensitization for dust mite
* pregnancy
* previous use of Acar'up

Primary outcomes:
measure: assessment of successful stepdown of inhaled corticosteroid using clinical evaluation
timeFrame: 4 months
measure: assessment of successful stepdown of inhaled corticosteroid using asthma scale: asthma control questionnaire (ACQ)
timeFrame: 4 months
measure: assessment of successful stepdown of inhaled corticosteroid using asthma quality of life questionnaire (AQLQ)
timeFrame: 4 months
Secondary outcomes:
measure: assessment of asthma control by the asthma control questionnaire questionnaire
timeFrame: 4 months
measure: assessment of asthma quality of life by the asthma quality of life questionnaire
timeFrame: 4 months
measure: assessment of rhinitis control by the rhinitis quality of life questionnaire
timeFrame: 4 months
Other outcomes:
Locations:
city: Brussels
country: Belgium
facility: CHu Saint Pierre
Study officials:
References:
Clinical trial NCT06777628: Immunophenotype of PBMC to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma
Official title: Immunophenotype of Peripheral Blood Mononuclear Cells to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Liver Cancer, Adult
Keywords: immunophenotype
HCC patients
immunotherapy
Lead sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
Sponsor class: OTHER
First posted: 2025-01-16
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with advanced hepatocellular carcinoma

Brief summary: The study is aimed to test the performance of a simple, easy, reproducible cytofluorimetric assay to complement imaging studies for:

* predicting response to immune-therapeutic regimens in HCC in the early phase of treatment,
* to rule out pseudo-progression,
* to early predict the escape from effectiveness of treatment.

Detailed description: * To assess the accuracy of biomarkers from an immunophenotypic test (CD8+, PD1+, PD-L1+, CTLA4+, LAG3+, CD8+PD1+, CD8+PDL1+ peripheral lymphocyte populations and circulating granulocytes) in predicting the response to immuno-therapy in patients affected by hepatocellular carcinoma (HCC).
* To compare the transcriptomic signatures of peripheral blood mononuclear cells (PBMC) of responders and non-responders (assessed at the first imaging study).

RNAseq data will be validated by RT-PCR in independent prospective cohorts.

Eligibility criteria: Inclusion Criteria:

* age ≥ 18 years
* diagnosis of HCC
* execution of laboratory tests and subsequent treatments and follow-up at our center.
* obtained written informed consent to the study participation

Exclusion Criteria:

* immune-related concomitant diseases
* HIV infection

Primary outcomes:
measure: To find predictive biomarkers of response to immunotherapy in HCC
timeFrame: at 3 month
Secondary outcomes:
measure: To compare the transcriptomic signatures of PBMC of responders and non-responders
timeFrame: At 3 months
Other outcomes:
Locations:
city: Bologna
country: Italy
facility: IRCCS-Azienda Ospedaliero-Universitaria di Bologna
state: Laura Gramantieri
Study officials:
affiliation: IRCCS Azienda Ospedaliero-Universitaria di Bologna
name: Laura Gramantieri
role: PRINCIPAL_INVESTIGATOR
References: